Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Updated ASH 2022 data showed 77% ORR at the high-dose cohort in heavily pretreated multiple myeloma patients, supporting HPN217's clinical promise but…
AbbVie passed on its option for HPN217, ending the partnership and puncturing Harpoon's path to a potential $200M+ payday; the opt-out reflected a crowded BCMA…
AbbVie's exit from the HPN217 program signaled diminished commercial appetite for differentiated BCMA assets in a market already crowded by approved CAR-Ts and…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Harpoon Therapeutics and AbbVie entered an exclusive worldwide option and license agreement for HPN217, a BCMA-targeting TriTAC for multiple myeloma, and expanded their TriTAC discovery collaboration. Harpoon received $50M upfront with up to $510M in total upfront, option exercise and milestone payments plus royalties. AbbVie terminated the HPN217 option in 2022.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Harpoon Therapeutics (this deal) | 2019 | $510M | — |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2019 deals · AbbVie Inc. deals · Hematology deals